Volume 12, Number 8—August 2006
Rat-bite Fever, Canada
Highlight and copy the desired format.
|EID||Schachter ME, Wilcox L, Rau N, Yamamura D, Brown S, Lee CH, et al. Rat-bite Fever, Canada. Emerg Infect Dis. 2006;12(8):1301-1302. https://dx.doi.org/10.3201/eid1208.060044|
|AMA||Schachter ME, Wilcox L, Rau N, et al. Rat-bite Fever, Canada. Emerging Infectious Diseases. 2006;12(8):1301-1302. doi:10.3201/eid1208.060044.|
|APA||Schachter, M. E., Wilcox, L., Rau, N., Yamamura, D., Brown, S., & Lee, C. H. (2006). Rat-bite Fever, Canada. Emerging Infectious Diseases, 12(8), 1301-1302. https://dx.doi.org/10.3201/eid1208.060044.|
To the Editor: Rat-bite fever was once considered an infection exclusive to children living in poverty; however, dense urban housing and changing pet-keeping practices may be altering this profile (1,2). To date, ≈200 cases of rat-bite fever have been reported in the United States (3), and a recent study reported a 2-fold increased incidence in California during the 1990s (1). We report on 2 cases that occurred in Ontario, Canada, in the early 2000s.
The first case occurred in a previously healthy 29-year-old man who was bitten on the finger by a pet rat. The wound healed spontaneously. After 24 hours, fever and emesis developed; 4 days later, diffuse maculopapular rash and migratory arthritis of the knees, ankles, and finger joints ensued. Physical examination showed a maculopapular rash over the lower extremities, an effusion of the left knee, and a warm, erythematous left ankle.
Laboratory investigations showed hemoglobin level of 134 g/L, leukocyte count of 16.0×109/L, and neutrophil count of 13.8×109/L. Aspiration of the knee produced 70 cm3 of cloudy fluid; synovial fluid analysis showed 666×106/L leukocytes with a predominance of neutrophils.
Ceftriaxone, 2 g once a day, was given intravenously for 7 days. Although symptoms improved within 24 hours, the effusion recurred within 48 hours of discontinuing the initial course of ceftriaxone. The knee was surgically drained, and ceftriaxone was continued for 5 weeks. Systemic symptoms and the effusion resolved.
The second case occurred in a previously healthy 9-year-old girl who had mucosal contact with a pet rat. She sought treatment after 7 days of generalized maculopapular and pustular rash and 10 days of fever and headache. She had an associated asymmetric, migratory arthritis.
Physical examination showed superficial scratches from the rat; temperature of 39.6°C; heart rate of 102 bpm; swelling, erythema, and decreased range of motion in several joints; and pustular lesions on the soles of the feet.
The patient’s leukocyte count was 8.3×109/L. Synovial fluid from the knee showed 45.5×106/L leukocytes with 89% neutrophils; the culture showed no growth. Gram stains of blood and pustule swabs showed large, pleomorphic, gram-negative bacilli with long filaments and irregular swellings. Growth occurred on the blood culture after 28 hours of aerobic incubation at 35°C in 10% horse serum. Characteristic puff-ball colonies of Streptobacillus moniliformis were seen in supplemented thioglycolate broth.
Identification of the organism was confirmed by using the Sherlock (MIDI Inc., Newark, DE, USA) system. The major cellular fatty acid components of the isolate matched an S. moniliformis reference strain. The patient received penicillin and gentamicin intravenously for 6 days and was discharged home with a 10-day regimen of amoxicillin. One year later, she remained asymptomatic.
Rat-bite fever commonly results from infection with the zoonotic pathogens S. moniliformis and Spirillum minus. S. moniliformis is more common in Western countries, and S. minus predominates in Asia (3). S. moniliformis colonizes the nasopharynx of healthy rats (4) and is transmitted by the bite or scratch of rats, squirrels, mice, guinea pigs, and, rarely, cats and other rodent predators. Occasionally, it is transmitted by ingestion of contaminated milk or water (5,6). The site of inoculation with S. moniliformis usually heals before systemic symptoms develop. After the incubation period of 1 to 22 days, patients experience fever, chills, myalgia, headache, and rash. The rash consists of macules, vesicles, and pustules on the extremities; soles and palms are frequently involved. Joint symptoms range from polyarthralgia to migratory polyarthritis with purulent effusions. A nonsuppurative migratory polyarthritis occurs in ≈50% of patients (5,7). In rare cases, rash and arthritis may be absent (8).
When S. minus (a spirochete) is introduced by rat bite, the bite wound initially heals but then ulcerates, followed by regional lymphadenopathy and a distinctive rash of red and purple plaques. Arthritic symptoms are rare (9).
Complications of rat-bite fever include destructive joint disease, pericarditis, endocarditis, abscesses, pneumonia, parotitis, pancreatitis, and, rarely, meningitis and amnionitis. Development of endocarditis results in a mortality rate of up to 50% (5).
S. moniliformis can be isolated and cultured from synovial fluid, blood, and abscesses. By contrast, S. minus has not been recovered on artificial media but can be seen by using dark-field microscopy with Giemsa or Wright stains.
Laboratory personnel must be notified when rat-bite fever is suspected because S. moniliformis does not grow in a routine sheep blood or MacConkey agar; it requires rat or horse serum, defibrinated blood, or ascitic fluid to sustain growth. Growth of S. moniliformis is inhibited by sodium polyanetholesulfonate, a substance that is added to blood culture bottles to inhibit the antimicrobial action of blood (4,8).
Although rat-bite fever is uncommon, it is increasingly seen as a result of changing patterns of urban living and pet-keeping practices. If unrecognized, this infection can have debilitating sequelae and can be life-threatening.
- Graves MH, Janda MJ. Rat-bite fever (Streptobacillus moniliformis): a potential emerging disease. Int J Infect Dis. 2001;5:151–4.
- Morse SS. Factors in the emergence of infectious disease. Emerg Infect Dis. 1995;1:7–15.
- Freels LK, Elliott SP. Rat bite fever: three case reports and a literature review. Clin Pediatr (Phila). 2004;43:291–5.
- Salmon RL, McEvoy MB. Rat-bite fevers. In: Zoonosis. Palmer SR, Soulsby S, Simpson DIH, editors. Toronto: Oxford Medical Publications; 1998. p. 187–90.
- Hambridge SJ, Ogle JW. Index of suspicion. Case 1. Diagnosis: rat-bite fever. Pediatr Rev. 2001;22:95–103.
- Parker F Jr, Hudson HP. The etiology of Haverhill fever (erythema arthriticum epidemicum). Am J Pathol. 1926;2:357–79.
- Washburn R. Streptobacillus moniliformis (Rat-bite fever). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Toronto: Churchill Livingstone Inc.; 2000. p. 2422–4.
- Lambe DW Jr, McPhedran AM, Mertz JA, Stewart P. Streptobacillus moniliformis isolated from a case of Haverhill fever: biochemical characterization and inhibitory effect of sodium polyanethol sulfonate. Am J Clin Pathol. 1973;60:854–60.
- Committee on Infectious Diseases, American Academy of Pediatrics. 2003 Red book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: The American Academy of Pediatrics; 2000. p. 482–3.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Christine H. Lee, Department of Pathology and Molecular Medicine, McMaster University. St. Joseph’s Healthcare, 50 Charlton Ave East, Hamilton, Ontario L8N 4A6, Canada; email
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 09, 2011
- Page last updated: December 09, 2011
- Page last reviewed: December 09, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)